Nonetheless, the treatment, which is largely similar to the one described for CIDP with comparably worse outcomes overall, is based primarily on the severity of neurological symptoms, rather than on the levels of IgM. This evidence concerns the gene CD40LG and chronic inflammatory demyelinating polyradiculoneuropathy.